"Immunotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
| Descriptor ID |
D007167
|
| MeSH Number(s) |
E02.095.465.425
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy".
This graph shows the total number of publications written about "Immunotherapy" by people in this website by year, and whether "Immunotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 0 | 2 | 2 |
| 2001 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2013 | 2 | 1 | 3 |
| 2015 | 1 | 0 | 1 |
| 2017 | 2 | 0 | 2 |
| 2021 | 2 | 2 | 4 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunotherapy" by people in Profiles.
-
A prospective multi-cohort study identifies and validates a 5-gene peripheral blood signature predictive of immunotherapy response in non-small cell lung cancer. Mol Cancer. 2024 Nov 06; 23(1):247.
-
Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy. Front Immunol. 2023; 14:1155778.
-
SLAM-family receptors come of age as a potential molecular target in cancer immunotherapy. Front Immunol. 2023; 14:1174138.
-
Advances in therapeutic targeting of immune checkpoints receptors within the CD96-TIGIT axis: clinical implications and future perspectives. Expert Rev Clin Immunol. 2022 Dec; 18(12):1217-1237.
-
Phase 1/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma. Head Neck. 2021 12; 43(12):3875-3887.
-
Adjuvant Therapy and Prognosticators of Survival in Head and Neck Mucosal Melanoma. Laryngoscope. 2022 03; 132(3):584-592.
-
Treatment Modalities and Survival Outcomes for Sinonasal Diffuse Large B-Cell Lymphoma. Laryngoscope. 2021 11; 131(11):E2727-E2735.
-
Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition. J Immunol Methods. 2021 03; 490:112956.
-
Immune Checkpoint Blockade for Breast Cancer. Cancer Treat Res. 2018; 173:155-165.
-
Epidermal Growth Factor Receptor (EGFR)-targeted Photoimmunotherapy (PIT) for the Treatment of EGFR-expressing Bladder Cancer. Mol Cancer Ther. 2017 10; 16(10):2201-2214.